NO20084187L - Medikamenter og proteiner - Google Patents

Medikamenter og proteiner

Info

Publication number
NO20084187L
NO20084187L NO20084187A NO20084187A NO20084187L NO 20084187 L NO20084187 L NO 20084187L NO 20084187 A NO20084187 A NO 20084187A NO 20084187 A NO20084187 A NO 20084187A NO 20084187 L NO20084187 L NO 20084187L
Authority
NO
Norway
Prior art keywords
drugs
medications
proteins
fragments
derivatives
Prior art date
Application number
NO20084187A
Other languages
English (en)
Inventor
Mark William James Ferguson
Hugh Gerard Laverty
Nick Occleston
Sharon O'kane
Emma Atkinson
Phillip Mellors
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of NO20084187L publication Critical patent/NO20084187L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SAMMENDRAG Det blir gitt bruk av monomersk TGF-ß3 eller fragmentere eller derivater som legemidler. Disse legemidlene skal fortrinnsvis omfatte monomerisk TGF-ß3 eller fragmenter eller derivater av dette. Legemidlene som leveres kan brukes i akselerasjonen av sårheling og/eller hemning av arrdannelse, i fremming av epitelgenerasjon eller i forebyggelse og/eller behandling av fibrosesykdommer.
NO20084187A 2006-03-11 2008-10-07 Medikamenter og proteiner NO20084187L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0604966.2A GB0604966D0 (en) 2006-03-11 2006-03-11 Medicaments and proteins
PCT/GB2007/000834 WO2007104946A2 (en) 2006-03-11 2007-03-12 Medicaments and proteins based on tgf-beta monomers for the treatment of wounds

Publications (1)

Publication Number Publication Date
NO20084187L true NO20084187L (no) 2008-10-07

Family

ID=36241467

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084187A NO20084187L (no) 2006-03-11 2008-10-07 Medikamenter og proteiner

Country Status (13)

Country Link
US (1) US7902150B2 (no)
EP (2) EP2359844A3 (no)
JP (1) JP2009543757A (no)
KR (1) KR20080100828A (no)
CN (1) CN101605555A (no)
AR (1) AR062773A1 (no)
BR (1) BRPI0708791A2 (no)
GB (1) GB0604966D0 (no)
IL (1) IL193700A0 (no)
MX (1) MX2008011707A (no)
NO (1) NO20084187L (no)
RU (1) RU2008140117A (no)
WO (1) WO2007104946A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
ES2900801T3 (es) 2004-12-22 2022-03-18 Nitto Denko Corp Portador de fármacos y kit de portador de fármacos para inhibir la fibrosis
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0604964D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0724204D0 (en) * 2007-12-12 2008-01-23 Renovo Ltd Methods for inhibition of scarring
GB0724203D0 (en) * 2007-12-12 2008-01-23 Renovo Ltd Methods for the inhibition of scarring
EP2670411B1 (en) * 2011-02-02 2019-04-10 Excaliard Pharmaceuticals, Inc. Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars
WO2023069629A1 (en) * 2021-10-20 2023-04-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating inflammatory bowel disease
WO2023206188A1 (en) * 2022-04-28 2023-11-02 Wenzhou Prarucom Bio-Chemical Technology Co. Method for alleviating pulmonary fibrosis using epidermal growth factor

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051848A (en) * 1976-03-01 1977-10-04 Levine Norman S Synthetic skin wound dressing
IL78197A (en) 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
US6559123B1 (en) * 1985-04-19 2003-05-06 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
AU1539188A (en) * 1987-05-04 1988-11-10 Bristol-Myers Squibb Company TGF-B2 and novel compositions having anti-neoplastic activity
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
WO1991005565A1 (en) 1989-10-18 1991-05-02 Creative Biomolecules, Inc. BIOSYNTHETIC CONSTRUCTS OF TGF-$g(b)
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
TW440566B (en) * 1994-07-25 2001-06-16 Novartis Ag Novel process for the production of biologically active dimeric protein
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
ES2196164T3 (es) 1995-07-25 2003-12-16 Novartis Ag Cristales de factor de crecimiento transformable beta.
WO1997023638A1 (fr) 1995-12-21 1997-07-03 Ajinomoto Co., Inc. Procede pour replier l'activine a humaine
WO1997041899A1 (en) * 1996-05-03 1997-11-13 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
EP1074620A1 (en) * 1999-08-06 2001-02-07 HyGene AG Monomeric protein of the TGF-beta family
JPH11335398A (ja) * 1998-05-22 1999-12-07 Hoechst Marion Roussel Kk 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
US6673341B2 (en) * 1998-07-06 2004-01-06 Beth Israel Deaconness Medical Center Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
RU2001111881A (ru) 1998-10-07 2003-06-20 Зингента Партисипейшнс Аг (Ch) Терапевтически активные протеины в растениях
JP2002539172A (ja) 1999-03-17 2002-11-19 ノバルティス アクチエンゲゼルシャフト Ｔｇｆ−ベータを含む医薬組成物
AU3269399A (en) * 1999-03-22 2000-10-09 Universitat Zurich Transforming growth factor (tfg) beta superfamily antagonists
AR027765A1 (es) 2000-04-03 2003-04-09 Monsanto Technology Llc Expresion y purificacion de polipeptidos bioactivos autenticos a partir de plantas
DE60127113T2 (de) * 2000-04-25 2007-06-14 Otsuka Pharmaceutical Co., Ltd. Gd3-mimetische peptide
US20040078851A1 (en) * 2000-05-02 2004-04-22 Ning Huang Production of human growth factors in monocot seeds
DE10026713A1 (de) 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
WO2002012336A2 (en) 2000-08-09 2002-02-14 Curis, Inc. TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
CA2441588A1 (en) 2001-03-23 2002-10-03 Biopharm Gesellschaft Zue Biotechnologischen Entwicklung Von Pharmaka Mbh Use of cytokines of the tgf-.beta. superfamily for the treatment and diagnosis of skin related disorders
WO2002099067A2 (en) 2001-06-05 2002-12-12 Oishi Karen K Gene expression and production of tgf-b proteins including bioactive mullerian inhibiting substance from plants
CA2496913A1 (en) 2002-09-27 2004-04-08 Centro De Ingenieria Genetica Y Biotecnologia Vector for the production of transplastomic angiosperm plants
WO2005084712A2 (en) * 2004-02-27 2005-09-15 Antisense Pharma Gmbh Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
WO2006023782A2 (en) 2004-08-19 2006-03-02 Biogen Ideca Ma Inc. Refolding transforming growth factor beta family proteins
US20060162026A1 (en) 2004-12-23 2006-07-20 Karen Oishi Expressing TGF-beta proteins in plant plastids
US7691816B2 (en) * 2005-07-12 2010-04-06 Renovo Ltd. Pharmaceutical compositions
GB0514262D0 (en) 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
GB0604964D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0617816D0 (en) 2006-09-11 2006-10-18 Renovo Ltd Nucleic acids and methods of protein expression

Also Published As

Publication number Publication date
BRPI0708791A2 (pt) 2011-06-14
KR20080100828A (ko) 2008-11-19
WO2007104946A2 (en) 2007-09-20
GB0604966D0 (en) 2006-04-19
CN101605555A (zh) 2009-12-16
IL193700A0 (en) 2011-08-01
JP2009543757A (ja) 2009-12-10
MX2008011707A (es) 2008-09-26
EP2359844A2 (en) 2011-08-24
EP2012812A2 (en) 2009-01-14
US7902150B2 (en) 2011-03-08
US20090137475A1 (en) 2009-05-28
RU2008140117A (ru) 2010-04-20
AR062773A1 (es) 2008-12-03
WO2007104946A3 (en) 2008-04-24
EP2359844A3 (en) 2011-09-14

Similar Documents

Publication Publication Date Title
NO20084187L (no) Medikamenter og proteiner
NO20081878L (no) Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
NO20092527L (no) Prolegemidler, fremgangsmate for fremstilling og anvendelse derav
CY1112813T1 (el) 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
NO20065195L (no) Terapeutiske enzymformuleringer og anvendelser derav
DK1543063T3 (da) Medikament levering
WO2008139122A3 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
UY28953A1 (es) Derivados heterocíclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
NO20092254L (no) Pulverformuleringer for valganciclovir
DK1771155T3 (da) Fremgangsmåde og sammensætning til behandling af rhinitis
CY1119580T1 (el) Νεα φαρμακα σκευασματα χρησιμα στη θεραπευτικη αγωγη της αϋπνιας
BR0311700A (pt) Processo para a produção de uma preparação em forma de pelìcula e preparação em forma de pelìcula
JP2010538020A5 (no)
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης
DE502004010514D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden
NO20080034L (no) Benzotiazol-2-on derivater som lipase og fosfolipaseinhibitorer
DE502005007472D1 (de) Desoxo-nonadepsipeptide
RS54185B1 (en) USE OF 24-ORDER
BRPI0715361B8 (pt) uso de polietileno glicol em inflamação relacionada com doenças ou distúrbios tópicos e cicatrização de ferimento
NO20082838L (no) 9-klor-15-deoksyprostaglandinderivater, fremgangsmate for fremstilling av disse, og anvendelse som medikamenter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application